Single-Dose In-Vivo CRISPR Therapy Achieves World's First Phase 3 Win, Validating Gene Editing Platform

On April 27, 2026, biology textbooks gained a new chapter. Intellia Therapeutics announced that its experimental drug, lonvoguran ziclumeran (lonvo-z), successfully met all primary and secondary endpoints in a pivotal Phase 3 clinical trial.[1][2]

The milestone marks the world's first Phase 3 victory for an in vivo CRISPR gene-editing therapy. Unlike previous CRISPR treatments that require extracting cells from the body, lonvo-z is administered via a single intravenous infusion, editing the patient's DNA directly inside their liver.[2]

The trial, known as HAELO, targeted hereditary angioedema (HAE), a rare and potentially life-threatening genetic disorder. HAE is characterized by severe, unpredictable swelling attacks that can affect the limbs, face, gastrointestinal tract, and airways, often requiring emergency intervention.[1]

These attacks are driven by the overproduction of a peptide called bradykinin. In patients with HAE, a genetic deficiency allows the kallikrein-kinin pathway to run unchecked, flooding the body with bradykinin and causing fluid to leak rapidly from blood vessels into surrounding tissues.[1][3]

Lonvo-z uses CRISPR-Cas9 technology to target the root of this pathway. Delivered via lipid nanoparticles—the same microscopic fat-bubble delivery vehicle utilized in mRNA COVID-19 vaccines—the CRISPR machinery travels systemically through the bloodstream directly to the liver.

Once inside the liver cells, the CRISPR complex acts as molecular scissors, seeking out and inactivating the KLKB1 gene. This specific gene is responsible for producing plasma prekallikrein; by permanently turning it off, the therapy halts the downstream production of bradykinin, effectively neutralizing the swelling mechanism at its source.[3]

The clinical data, simultaneously published in The New England Journal of Medicine and presented at the EAACI congress, exceeded both investor and clinical expectations. Among the 80 patients randomized in the trial, those receiving lonvo-z experienced an 87% reduction in monthly HAE attacks compared to the placebo group.[1]

The secondary endpoints painted an even more compelling picture of a functional cure. During the six-month efficacy evaluation period, 62% of patients treated with the CRISPR therapy were entirely attack-free and required no other preventative medications, compared to just 11% in the placebo cohort.[1]

Furthermore, attacks requiring on-demand rescue treatments plummeted by 89%, and moderate-to-severe attacks fell by 91%. Patients also reported a 17-point improvement on the Angioedema Quality of Life score, well above the 6-point threshold considered clinically meaningful by physicians.[3]

To understand the magnitude of this achievement, it helps to look at the current state of gene editing. In late 2023, regulators approved Casgevy, the world's first CRISPR therapy, for sickle cell disease. However, Casgevy is an ex vivo therapy.[2]

Ex vivo treatments require patients to undergo grueling chemotherapy to wipe out their bone marrow, after which their previously extracted and lab-edited stem cells are reinfused. It is a highly complex, expensive, and physically taxing process that limits the therapy to specialized transplant centers.[2]

Lonvo-z, by contrast, is administered in a standard outpatient setting. The ability to let the body do the work—using lipid nanoparticles to ferry the editing tools to the right organ—removes the need for cellular extraction and chemotherapy, vastly expanding the accessibility and scalability of genetic medicine.

Because CRISPR makes permanent changes to the genome, safety has been the primary concern for regulators. In the HAELO trial, lonvo-z demonstrated a highly favorable safety profile, with no serious adverse events reported in the treatment arm.[1]

The most common side effects were mild to moderate infusion-related reactions, headaches, and fatigue, all of which resolved quickly. The FDA's comfort with this safety data is notable, especially given that Intellia recently navigated a temporary clinical hold on a separate in vivo CRISPR trial for a different disease, ATTR amyloidosis, which has since been lifted.

If approved, lonvo-z will enter a highly competitive market. Current HAE treatments, such as Takeda's Takhzyro and BioCryst's Orladeyo, are highly effective at preventing attacks but require chronic administration—either regular subcutaneous injections or daily pills.[1]

Intellia's pitch to patients and insurers is the value of a 'one and done' approach. A single infusion could free patients from a lifetime of chronic medication, alleviating the psychological burden of unpredictable attacks and the cumulative financial costs of lifelong pharmaceutical dependence.

Intellia has already initiated a rolling Biologics License Application with the U.S. Food and Drug Administration. The company anticipates completing the submission in the second half of 2026, targeting a commercial launch in the first half of 2027.[1]

Beyond HAE, the success of lonvo-z serves as a definitive proof-of-concept for the entire in vivo gene-editing field. Companies like CRISPR Therapeutics, Beam Therapeutics, and Verve Therapeutics are rapidly advancing similar nanoparticle-delivered therapies for much larger indications, including cardiovascular disease.[2]

The HAELO trial results represent more than just a new therapy for a rare disease. They mark the moment when CRISPR transitioned from a complex, lab-bound cellular procedure into a straightforward, systemic medicine, officially opening the door to the next generation of genetic cures.[2]